SCHEMBL1450337

SCHEMBL1450337

OCc1cccc(Br)c1O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.44
ACHE P22303 1/20 0.44
GABRA1 P14867 3/20 0.41
GABRB2 P47870 3/20 0.41
APOBEC3G Q9HC16 1/20 0.38
EGFR P00533 6/20 0.38
ERBB2 P04626 5/20 0.38
TAAR1 Q96RJ0 1/20 0.37
PDCD1 Q15116 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
IDO1 P14902 2/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
TSHR P16473 1/20 0.34
ALOX12 P18054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10557019 0.82 CA2 (0.41) CA2ACHEGABRA1GABRB2EGFR
SCHEMBL196227 0.82 GABRA1 (0.57) CA2GABRA1GABRB2APOBEC3GEGFR
SCHEMBL1004778 0.79 GABRA1 (0.70) CA2ACHEGABRA1GABRB2EGFR
SCHEMBL9715113 0.79 PARP1 (0.36) KDM4ELMNATP53MAPTTSHR
SCHEMBL608328 0.78 GABRA1 (0.42) GABRA1GABRB2APOBEC3GTAAR1PDCD1
SCHEMBL6942317 0.78 APOBEC3G (0.39) CA2GABRA1GABRB2APOBEC3GTAAR1
Hydrochloric Acid SCHEMBL25305592 0.77 CA2 (0.45) CA2ACHEGABRA1GABRB2EGFR
SCHEMBL110893 0.77
SCHEMBL2116718 0.76 PARP1 (0.41) GABRA1GABRB2APOBEC3GTAAR1PDCD1
SCHEMBL29790993 0.76 APOBEC3G (0.38) GABRA1GABRB2APOBEC3GTAAR1PDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552791-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-02-17 US disclosed
EP-4143183-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 EP disclosed
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2025-07-03 US disclosed
CN-118530083-A Novel method for selectively removing bromine atoms on aromatic ring 嘉兴学院 2024-08-23 CN disclosed
WO-2024129896-A1 INHIBITORS OF PROCASPASE-6 ACTIVATION AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 WO disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
EP-4143183-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-03-08 EP disclosed
CN-115667250-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-01-31 CN disclosed
WO-2021219019-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-11-04 WO disclosed
WO-2011121002-A1 HYDROXYLATED PHOSPHORYLATED CONTRAST ENHANCEMENT AGENTS GENERAL ELECTRIC COMPANY (US) 2011-10-06 WO disclosed
US-7910018-B2 Compounds for use in liquid crystal devices QINETIQ LIMITED (GB) 2011-03-22 US disclosed
US-7687664-B2 Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-30 US disclosed
US-20090066905-A1 Componds for use in liquid crystal devices QINETIQ LIMITED (GB) 2009-03-12 US disclosed
EP-1814870-A2 BENZO-1,3-DIOXANES FOR USE IN LIQUID CRYSTAL DEVICES Qinetiq Limited (GB) 2007-08-08 EP disclosed
WO-2006048620-A2 BENZO-1, 3-DIOXANES FOR USE IN LIQUID CRYSTAL DEVICES QINETIQ LIMITED (GB) 2006-05-11 WO disclosed
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-10-28 US disclosed
EP-1394147-A1 CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME Eisai Co., Ltd. (JP) 2004-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR CA2 2913/4885ACHE 2378/4885GABRA1 884/4885
US-20090066905-A1 Componds for use in liquid crystal devices FZD7, CFD, PYCARD CA2 1277/4885ACHE 1728/4885GABRA1 4667/4885
US-12552791-B2 Heterocyclic GLP-1 agonists GLP1R, NPY1R, NPY2R CA2 222/4885ACHE 3336/4885GABRA1 505/4885
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR CA2 2913/4885ACHE 2378/4885GABRA1 884/4885
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same GPR119, NR3C1, INSR CA2 525/4885ACHE 4721/4885GABRA1 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.